David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody ® First-in-human study enrolling adult patients with ...
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold ...
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a ...
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- , ...
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...
Hosted on MSN10h
How Is Leukemia Diagnosed?Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...
Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback